Study Overview: This trial tests four drugs: vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib in patients with worsening meningiomas, a type of brain tumor. These drugs aim to stop tumor growth by blocking enzymes that help cells grow.

Key Points:

• This study involves taking medication orally and participating in cycles that last 28 days.
• Participants are assigned to one of four treatments based on specific genetic mutations in their tumors.
• After treatment, participants will be monitored every 6 months for up to 5 years.

Eligibility: To join, participants must have a specific type of brain tumor confirmed by tests, and specific genetic mutations in their tumors. They should not have certain health conditions such as uncontrolled diabetes, liver disease, or major recent surgeries. Participants must be stable on steroid doses and cannot be pregnant or nursing.

Considerations: Before joining, it's important to discuss potential side effects and the requirement for regular monitoring with your doctor. Participants need to meet specific health criteria to ensure safety and effectiveness of the treatment.